Tucatinib (Tukysa) is an oral small-molecule TKKI that selectively inhibits the HER2 receptor, blocking the proliferation of HER2-positive cancer cells and interfering with tumor growth and survival. This evidence concerns the gene ERBB2 and neoplasm.